Business Wire

GSMA Mobile IoT Initiative Welcomes First Low Power Wide Area Solutions at Mobile World Congress

Del

The first live demonstrations of Low Power Wide Area (LPWA) solutions in licensed spectrum will be on display at this year’s Mobile World Congress in Barcelona, the GSMA announced today. Visitors will experience a diverse range of solutions underpinned by three complementary technology standards known as Narrow Band IoT (NB-IoT), Extended Coverage EGPRS (EC-EGPRS) and LTE Machine Type Communication (Cat-M). The GSMA’s Mobile IoT Initiative has aligned the mobile industry behind these standards, which have been accepted by 3GPP for Release 13. The availability of commercial solutions in 2016 will remove market fragmentation, provide market reassurance and help to accelerate the Internet of Things (IoT) through the availability of very low cost, mobile operator-connected devices.

“LPWA is an emerging, high-growth area of the Internet of Things but it requires common, global standards in licensed spectrum in order for it to scale effectively and deliver secure, reliable and robust performance,” said Alex Sinclair, Chief Technology Officer, GSMA. “With high-quality managed networks, mobile operators are well placed to deliver these industry standard solutions which offer customers a clear choice and we are excited to see the industry move so quickly to provide commercial solutions.”

GSMA Mobile IoT Initiative

The Mobile IoT Initiative is supported by 30 of the world’s leading mobile operators, OEMs, chipset, module and infrastructure companies¹, and is designed to accelerate the commercial availability of LPWA solutions in licensed spectrum. LPWA networks are designed for M2M applications that have low data rates, require long battery lives and operate unattended for long periods of time, often in remote locations. They are expected to be used for a wide variety of applications such as industrial asset tracking, safety monitoring, water and gas metering, smart grids, city parking, vending machines and city lighting.

Mobile IoT Technology Demonstrations at Mobile World Congress.

There are already a number of commercial trials and pilots of LPWA solutions underway around the world; however, at Mobile World Congress visitors will be amongst the first to try them out for themselves. At the GSMA Innovation City located at Stands 3A11 and 3A31 in Hall 3, Fira Gran Via there will be a number of demos including:

  • Smart Agriculture/Connected Vineyard : Ericsson, Intel and Orange will showcase how EC-EGPRS will address the challenge of extending coverage to difficult-to-reach indoor locations such as basements as well as remote rural locations, such as vineyards and farms.
  • Connected eBike : Ericsson, Intel and Nokia will showcase an innovative bike tracking solution that utilises NB-IoT technology to track the real-time location and status of eBikes through urban underground or even rural environments with lower signal levels.
  • Fleet tracking and Smart Grid monitoring : Ericsson and Intel will demonstrate how Cat-M technology supports extended coverage in underground or rural areas for IoT applications such as fleet management and smart grid management.
  • Mobile IoT Water Meter : Huawei, Neul, Vodafone and u-blox will demonstrate how NB-IoT technology helps to provide real time usage information and fault management using live results relayed from Vodafone’s Proof of Concept in Valencia, Spain.
  • Connected Consumer and Industrial Devices: Sierra Wireless will demonstrate how Cat-M will be used for a variety of consumer devices, such as connected shoes, wearables and healthcare devices, as well as industrial devices, such as smart electric meters.
  • Pet Tracking: Huawei and Vodafone will be showing how NB-IoT can be used to make sure your beloved pets are kept safe and sound.

Global NB-IoT Summit

The GSMA NB-IoT Forum, which is part of the GSMA’s wider Mobile IoT initiative, will also host its first ever Global NB-IoT Summit at Mobile World Congress. The half-day event will explore the value of NB-IoT technologies from an operator and OEM perspective and examine how the industry is working together to realise the full potential of the technology. The GSMA NB-IoT Forum was launched by major mobile operators, network suppliers and chipset and module manufacturers to accelerate the ecosystem for NB-IoT solutions².The event will take place on Sunday, 21 February 2016. For further information and to register please follow this link: www.gsma.com/connectedliving/events/gsma-global-nb-iot-summit/.

Connected Living Seminar at Mobile World Congress 2016

The GSMA will also host a seminar on Wednesday, February 24 with industry experts at MWC 2016 covering the impact of LPWA networks. To register or for more information please go to: www.gsma.com/connectedliving/events/connected-living-seminar-securely-scaling-the-internet-of-things/

MWC 2016: Get Involved at Mobile World Congress 2016

For more information on the 2016 Mobile World Congress including how to attend, exhibit or sponsor, visit www.mobileworldcongress.com. Follow developments and updates on Mobile World Congress on Twitter @GSMA using #MWC16, on our LinkedIn company page http://gsma.at/GSMALinkedIn, or on Facebook at www.facebook.com/gsma. For more information on the GSMA Innovation City, follow #gsmainnovationcity.

-ENDS-

Notes to Editors

1.) The GSMA’s Mobile IoT Initiative is backed by key industry players including AT&T, Bell Canada, Bermuda Digital Communications, China Mobile, China Telecom, China Unicom, Deutsche Telekom, Ericsson, Etisalat, Huawei, Gemalto, Intel, KDDI, KT, LG Uplus, Nokia, NTT DOCOMO, Oberthur Technologies, Ooredoo, Orange, Qualcomm Incorporated, Sequans, Sierra Wireless, Singtel, Telecom Italia, Telefonica, Telenor, Telstra, u-blox, Verizon Wireless and Vodafone.

2.) The GSMA NB-IoT Forum is supported by key industry players including ARM, China Mobile, China Unicom, DT, Ericsson, Etisalat, GTI, Huawei, Intel, KDDI, KT, LG Uplus, Nokia, NTT DOCOMO, Oberthur Technologies, Qualcomm Incorporated, Telecom Italia, Telefonica, u-Blox and Vodafone.

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 250 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Charlie Meredith-Hardy
+44 7917 298428
CMeredith-Hardy@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom